Through analysis of genetic expression profiles, researchers at Vanderbilt-Ingram Cancer Center identified 6 subtypes of triple-negative breast cancer, including 2 basal-like, 1 immunomodulatory, 1 mesenchymal, 1 mesenchymal stem–like, and 1 luminal androgen receptor. The researchers used cell line models to test if these data can inform therapy selection, finding direct correlations: basal-like with cisplatin; mesenchymal and mesenchymal stem–like with NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib; and luminal androgen receptor with bicalutamide. They concluded that their findings “may be useful in biomarker selection, drug discovery, and clinical trial design that will enable alignment of [triple-negative breast cancer] patients to appropriate targeted therapies.”
The complete study is published in the July issue of the Journal of Clinical Investigation and available free online (http://www.jci.org/articles/view/45014).
To sign up for our newsletter or print publications, please enter your contact information below.
